Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

BACKGROUND: Recent large-scale randomized studies have demonstrated that 2 new hormone preparations (abiraterone and enzalutamide) prolong survival in docetaxel-treated or -naïve castration-resistant prostate cancer patients. However, no studies have directly compared antitumor effects between these...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JMIR Res Protoc
Main Authors: Hara, Isao, Yamashita, Shimpei, Nishizawa, Satoshi, Kikkawa, Kazuro, Shimokawa, Toshio, Kohjimoto, Yasuo
Formato: Artigo
Idioma:Inglês
Publicado em: JMIR Publications 2018
Assuntos:
Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086929/
https://ncbi.nlm.nih.gov/pubmed/30054264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2196/11191
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados